Goldman Sachs Maintains Buy on Incyte, Lowers Price Target to $98
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Incyte (NASDAQ:INCY) but lowers the price target from $114 to $98.
November 02, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Incyte but lowers the price target from $114 to $98.
The news is directly related to Incyte. While the Buy rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100